The epidermal growth factor receptor (EGRF) in lung cancer

doi:10.1186/s40247-015-0013-z

. 2015 Feb 24:3:1.

doi: 10.1186/s40247-015-0013-z. eCollection 2015.

The epidermal growth factor receptor (EGRF) in lung cancer

Enric Carcereny¹, Teresa Morán¹, Laia Capdevila², Sara Cros³, Laia Vilà¹, Maria de Los Llanos Gil¹, Jordi Remón⁴, Rafael Rosell⁵

Affiliations

¹ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
² Hospital Santa Tecla, Tarragona, Spain.
³ Hospital de Granollers, Barcelona, Spain.
⁴ Hospital de Mataró, Barcelona, Spain.
⁵ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain ; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona Spain ; Fundación Molecular Oncology Research, Sabino Arana 5-19, Barcelona, Spain.

PMID: 25810955
PMCID: PMC4366432
DOI: 10.1186/s40247-015-0013-z

The epidermal growth factor receptor (EGRF) in lung cancer

Enric Carcereny et al. Transl Respir Med. 2015.

. 2015 Feb 24:3:1.

doi: 10.1186/s40247-015-0013-z. eCollection 2015.

Authors

Enric Carcereny¹, Teresa Morán¹, Laia Capdevila², Sara Cros³, Laia Vilà¹, Maria de Los Llanos Gil¹, Jordi Remón⁴, Rafael Rosell⁵

Affiliations

¹ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain.
² Hospital Santa Tecla, Tarragona, Spain.
³ Hospital de Granollers, Barcelona, Spain.
⁴ Hospital de Mataró, Barcelona, Spain.
⁵ Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Department of Medicine, Badalona, Barcelona Spain ; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona Spain ; Fundación Molecular Oncology Research, Sabino Arana 5-19, Barcelona, Spain.

PMID: 25810955
PMCID: PMC4366432
DOI: 10.1186/s40247-015-0013-z

Abstract

In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.

Keywords: EGFR; Epidermal growth factor receptor; Lung cancer; TKI; Tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

**Figure 1**
**Epidermal growth factor receptor pathway.**

**Figure 2**
**Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor.**

See this image and copyright information in PMC

Cited by

Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Saida K, Murase T, Ito M, Fujii K, Takino H, Masaki A, Kawakita D, Ijichi K, Tada Y, Kusafuka K, Iida Y, Onitsuka T, Yatabe Y, Hanai N, Hasegawa Y, Shinomiya H, Nibu KI, Shimozato K, Inagaki H. Saida K, et al. Oncotarget. 2018 Mar 30;9(24):17043-17055. doi: 10.18632/oncotarget.24818. eCollection 2018 Mar 30. Oncotarget. 2018. PMID: 29682203 Free PMC article.
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.
Franks SE, Briah R, Jones RA, Moorehead RA. Franks SE, et al. Oncotarget. 2016 Jan 19;7(3):3297-316. doi: 10.18632/oncotarget.6489. Oncotarget. 2016. PMID: 26654940 Free PMC article.
Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR.
Cao X, Zhong W, Guo S, Zhang Z, Xie C. Cao X, et al. Open Med (Wars). 2022 Apr 27;17(1):816-825. doi: 10.1515/med-2022-0472. eCollection 2022. Open Med (Wars). 2022. PMID: 35582197 Free PMC article.
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
Van Der Steen N, Keller K, Dekker H, Porcelli L, Honeywell RJ, Van Meerloo J, Musters RJP, Kathmann I, Frampton AE, Liu DSK, Ruijtenbeek R, Rolfo C, Pauwels P, Giovannetti E, Peters GJ. Van Der Steen N, et al. J Cell Physiol. 2020 Nov;235(11):8085-8097. doi: 10.1002/jcp.29463. Epub 2020 Jan 20. J Cell Physiol. 2020. PMID: 31960422 Free PMC article.
Discovery of potential epidermal growth factor receptor inhibitors from black pepper for the treatment of lung cancer: an in-silico approach.
Elekofehinti OO, Adetoyi IR, Popoola HO, Ayodeji FO, Taiwo FA, Akinjiyan MO, Koledoye OF, Iwaloye O, Adegboyega AE. Elekofehinti OO, et al. In Silico Pharmacol. 2024 Apr 8;12(1):28. doi: 10.1007/s40203-024-00197-1. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38601803

See all "Cited by" articles

References

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. doi: 10.1056/NEJMoa011954. - DOI - PubMed
1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. doi: 10.1056/NEJMoa061884. - DOI - PubMed
1. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–902. doi: 10.1200/JCO.2012.47.1102. - DOI - PubMed
1. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22. doi: 10.4103/1477-3163.123972. - DOI - PMC - PubMed
1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67. doi: 10.1093/emboj/19.13.3159. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. doi: 10.1056/NEJMoa011954. - DOI - PubMed

[2] Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. doi: 10.1056/NEJMoa011954. - DOI - PubMed

[3] Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. doi: 10.1056/NEJMoa061884. - DOI - PubMed

[4] Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. doi: 10.1056/NEJMoa061884. - DOI - PubMed

[5] Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–902. doi: 10.1200/JCO.2012.47.1102. - DOI - PubMed

[6] Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–902. doi: 10.1200/JCO.2012.47.1102. - DOI - PubMed

[7] Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22. doi: 10.4103/1477-3163.123972. - DOI - PMC - PubMed

[8] Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22. doi: 10.4103/1477-3163.123972. - DOI - PMC - PubMed

[9] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67. doi: 10.1093/emboj/19.13.3159. - DOI - PMC - PubMed

[10] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67. doi: 10.1093/emboj/19.13.3159. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The epidermal growth factor receptor (EGRF) in lung cancer

Affiliations

The epidermal growth factor receptor (EGRF) in lung cancer

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous